Tokyo, Aug. 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059775) titled 'Research for novel markers reflecting pancreatic beta-cell disorders' on Aug. 31.

Study Type: Observational

Primary Sponsor: Institute - Kansai Electric Power Medical Research Institute

Condition: Condition - Diabetes Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Identifying markers that more accurately reflect pancreatic b-cell disorders by using patients with type 1 diabetes as a stepping stone to a more predictable prognosis of b-cell function, which is a current challenge. Basic objectives2 - Others

Eligibility: Age-lower limit - 18 years-old = Gender - Male and Female Key inclusion criteria - Selection criteria: 1) Islet-associated autoantibody-positive diabetic patients between 18 and 80 years of age and those with normal glucose tolerance, patients with type 2 diabetes attending our hospital. 1-A) Normal glucose-tolerant patients are those with fasting blood glucose <110 mg/dl or HbA1c <6.2% at a check-up within the past year, recruited on the hospital website. 2) Persons judged by the attending physician to be able to tolerate the glucagon tolerance test 3) Persons who do not meet the following exclusion criteria Key exclusion criteria - Exclusion criteria: 1) Persons strongly suspected of suffering from dementia or psychiatric disorders 2) Patients with severe renal or hepatic dysfunction 3) Persons who are allergic to glucagon 4) Persons deemed unsuitable for this clinical study by the principal investigator or research assistant. Target Size - 50

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2024 Year 01 Month 10 Day Date of IRB - 2024 Year 02 Month 12 Day Anticipated trial start date - 2024 Year 04 Month 01 Day Last follow-up date - 2027 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065015

Disclaimer: Curated by HT Syndication.